is the identification of in-hospital complication (pneumonia), which should be actively monitored in these patients.

References:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2020-eular.5129

**Clinical utility of the Ward triangle (W) of bone densitometry:** Data from an FLS unit

J. Rosas1, A. Pons1, C. Cano1, E. Ivans2, M. Lorente Betoret2, J. M. Senabre Gallego1, G. Santos Soler1, J. A. Bernallí2, J. A. García-Gómez3, X. Barberon behalf of AIRE-MB Group. 1Hospital Marina Baixa, Rheumatology, Villajoyosa (Alicante), Spain; 2Hospital Marina Baixa, Rheumatology, Villajoyosa (Alicante), Spain; 3Hospital General Universitario de Elche, Infectious Disease, Elche, Spain; 4Universidad Miguel Hernández de Elche, CIO, Elche (Alicante), Spain

Objectives: To evaluate the clinical utility of Ward’s triangle (W) of bone densitometry (BMD) of the hip in a population of postmenopausal women referred to BMD from a FLS Unit coordinated by Rheumatology (FLS-REU).

Methods: Retrospective study, which includes, after informed consent, postmenopausal women referred by any department of specialized medicine or primary care medicine, to the FLS-REU Unit of our center, during the period of February 2010 to October 2019. General patient data were collected (age, gender), and risk factors for OP. BMD of the lumbar spine (CL) and hip (femoral neck, total hip and W) was performed, except if there was lumbar surgery, severe scoliosis, or a bilateral hip prosthesis. The BMD outcome was distributed in normal (T index [Ts] < -1 SD) and osteopenia (Ts: -1.1 to -2.5 SD) and OP (Ts: < -2.5 DE to -3 DE) or severe OP (Ts: < -3 DE).

Results: 5,740 postmenopausal women referred for BMD are included, with the W result available (Table 1). The result of the mean Ts (SD) was: in CL: -1.49 (1.48) SD, femoral neck: -1.33 (1.11) SD and in W: -2.05 (1.12) SD. In 947 (16%) women, the W was normal, with a mean Ts: -0.28 (1.12) SD; osteopenia in 2,606 (45%): -1.83 (1.12) SD and OP in 2,197 (39%) SD, of which 1,010 (61%) had mild-moderate OP and 967 (49%), severe OP.

The table shows the BMD results of W and CL, the correlation coefficient between them being 0.52 (0.50-0.5), P < 0.001, although with a Kappa coefficient of 0.26 (0.24-0.28, P = 0). The probability that a result in W of normal BMD is normal also in CL is 73% (70%–76%), in osteopenia in both: 47% (45%–49%) and OP: 46% (44%–48%). In the analysis by ROC curve, the cut-off point of Ts in W and CL is 73% (70%–76%), in osteopenia in both: 47% (45%–49%) and OP: 46% (44%–48%).

Conclusion: 1) For clinical practice, the usefulness of the W result is low, although if the BMD result is normal, there is a 73% probability that in CL it will also be 2. The correlation between the result of W and CL, although significant, is slight. 3) The cut-off points of Ts, with better sensitivity and specificity, that correlate a W osteopenia or osteoporosis with the result in CL is -1.65 and -2.35 SD, respectively.

Disclosure of Interests: The study was supported by a research grant from the Association for Research in Rheumatology of the Marina Baixa (AIRE-MB).

DOI of Interest: None declared

**AB0913 Predicting patients at risk of fragility fracture with normal bone mineral density: an observational study**

C. Saleh1, M. Bukhari1, S. M. Bilgrami1. 1Royal Lancaster Infirmary, Rheumatology, Lancaster, United Kingdom

Background: There is an increased risk of low-trauma fracture as bone mineral density (BMD) decreases, however a large proportion of these fragility fractures occur in those without osteoporosis or osteopenia. The widely used FRAX tool uses femoral neck (FN) BMD, amongst other parameters, to predict fracture risk. In those with normal BMD, data is lacking on the weight these other parameters hold in predicting future risk. Indeed, FN BMD can be facultative in the estimation of risk when using FRAX.

Objectives: To establish predictors of fragility fracture in a patient cohort referred for BMD estimation, subsequently found to have bilateral FN BMD of greater than 1.

Methods: A cohort of patients in the North West of England referred between 2004 and 2014 for BMD estimation, with both left and right FN BMD of greater than 1 were identified, then patient parameters identified and analysed, including age at scan, gender, current smoker history of 3 or more units per day, smoking status, rheumatoid arthritis (RA), and steroid exposure. Patients with fragility fracture were compared with those without fracture. Chi-square test and T test were applied to categorical and continuous data respectively. Further univariate and multivariate logistic regression models were fitted to determine parameters associated with future fracture risk.

Results: 619 patients with normal BMD FN of greater than 1 were identified (542 (87.56%) were female). 92 (14.86%) patients had a fragility fracture. Mean left FN BMD was 1.91 (SD 0.71), and mean right FN BMD was 1.92 (SD 0.68). Results of the univariate and multivariate logistic regression models are shown in Table 1 below.

Table 1. Logistic regression analysis of patient parameters with unadjusted and adjusted odds ratios for fragility fracture

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Unadjusted odds ratio</th>
<th>Odds ratio adjusted for age (95% CI)</th>
<th>Odds ratio adjusted for age and gender (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at scan (years)</td>
<td>0.99 (0.98-1.01)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Gender</td>
<td>1.37 (0.66, 2.84)</td>
<td>1.34 (0.64, 2.80)</td>
<td>-</td>
</tr>
<tr>
<td>BMD at left hip</td>
<td>0.94 (0.03, 4.50)</td>
<td>0.97 (0.03, 4.37)</td>
<td>0.93 (0.03, 4.78)</td>
</tr>
<tr>
<td>BMI</td>
<td>1.07 (1.03, 1.10)</td>
<td>1.07 (1.03, 1.10)</td>
<td>1.07 (1.03, 1.10)</td>
</tr>
<tr>
<td>Fat mass</td>
<td>1.00 (1.00, 1.00)</td>
<td>1.00 (1.00, 1.01)</td>
<td>1.00 (1.00, 1.01)</td>
</tr>
<tr>
<td>Parent fractured hip</td>
<td>0.99 (0.57, 1.70)</td>
<td>0.97 (0.56, 1.68)</td>
<td>0.94 (0.54, 1.64)</td>
</tr>
<tr>
<td>Alcohol (3 or more units/day)</td>
<td>1.16 (0.47, 2.86)</td>
<td>1.16 (0.47, 2.87)</td>
<td>1.16 (0.47, 2.89)</td>
</tr>
<tr>
<td>Current smoker</td>
<td>1.40 (0.89, 2.21)</td>
<td>1.40 (0.89, 2.21)</td>
<td>1.42 (0.90, 2.23)</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>0.83 (0.32, 2.19)</td>
<td>0.85 (0.32, 2.24)</td>
<td>0.86 (0.34, 2.27)</td>
</tr>
<tr>
<td>Steroid exposure</td>
<td>0.53 (0.30, 0.96)</td>
<td>0.53 (0.30, 0.96)</td>
<td>0.54 (0.30, 0.98)</td>
</tr>
</tbody>
</table>

Conclusion: Steroid exposure and body composition parameters influence fracture risk in this group of patients with normal BMD, further work will be done looking at the types of fractures and other parameters in this group of patients. Disclosure of Interests: Christopher Saleh: None declared, Marwan Bukhari Speakers bureau: Bristol-Myers Squib, UCBC celltech, Roche/Chugai, Pfizer, Abbvie, Merck, Menarini, Sanofi-aventis, Eli-Lilly, Janssen, Amgen and Novartis., Syed Mujtaba Bilgrami Speakers bureau: Pfizer

DOI: 10.1136/annrheumdis-2020-eular.4544

**AB0914 Bone loss and new fractures with denosumab treatment**

C. Sanguesa1, I. Casafont-Solé1, A. Nac1, S. Holgado Pérez2, M. Martínez-Morillo3, M. Aparicio Rovira1, A. Prior-Espanol1, M. Aparicio Espinari1, A. Riveros1, L. Mateo1, A. Olive1, L. Gilfe1. 1Germanas Tias i Pujol University Hospital, Rheumatology, Badalona, Spain

References: